Trial Profile
Japan-Based clinical ReseArch Network for Diabetes Registry.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms J-BRAND Registry
- 30 Mar 2021 Status changed from active, no longer recruiting to completed.
- 01 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 18 Nov 2013 Planned end date changed from 30 Jun 2017 to 31 Dec 2017 as reported by University Hospital Medical Information Network - Japan.